Guy C Jones1, Tuo Dong2, Charles B Simone3, Susan Stinson4. 1. Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: guy.jones@nih.gov. 2. Howard University College of Medicine, Washington, DC. 3. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA. 4. Department of Radiation Oncology, Suburban Hospital, Johns Hopkins Medicine, Bethesda, MD.
Abstract
BACKGROUND: Findings of the American College of Surgeons Oncology Group (ACOSOG) Z11 trial have proven controversial, leaving physicians divided over which patients with positive sentinel lymph nodes (+SLNs) benefit from axillary lymph node dissection (ALND). We reviewed our experience at our institution with Z11-eligible patients who did not undergo ALND and explored factors that predicted for positive lymph nodes (+LNs) on ALND after 1 to 2 +SLNs to determine which patients benefit from adjuvant therapy. MATERIALS AND METHODS: All breast cancer pathology reports from our institution containing the word "sentinel" between July 1998 and December 2001 were reviewed. We obtained follow-up information on patients meeting Z11 eligibility criteria who did not undergo ALND. We also compared pathological characteristics between patients with 1 to 2 +SLNs and +LNs on ALND to those with no further +LNs. RESULTS: Of the 432 pathology reports reviewed, 38 were from patients meeting Z11 criteria who did not undergo ALND. At a median follow-up of 11.9 years, these patients had 5-year overall survival (OS) of 93.3% and 10-year OS of 79.3%. No patient had recurrent disease in the axilla. Of the 80 patients with 1 to 2 +SLNs who underwent ALND, tumors with +LNs on ALND were generally larger, nonductal histology, more likely to be estrogen receptor positive (ER(+)) and progesterone receptor positive (PR(+)), and less likely to be HER2(+). CONCLUSION: Our institution's 5-year OS (93.3%) for Z11-eligible patients closely resembled those from the Z11 trial (92.5%) and our 10-year data provide evidence of what to expect for Z11-enrolled patients with continued follow-up. Larger tumor, nonductal, ER(+), PR(+), and HER2- were predictive for further +LNs on ALND, which might reflect surgical bias. Published by Elsevier Inc.
BACKGROUND: Findings of the American College of Surgeons Oncology Group (ACOSOG) Z11 trial have proven controversial, leaving physicians divided over which patients with positive sentinel lymph nodes (+SLNs) benefit from axillary lymph node dissection (ALND). We reviewed our experience at our institution with Z11-eligible patients who did not undergo ALND and explored factors that predicted for positive lymph nodes (+LNs) on ALND after 1 to 2 +SLNs to determine which patients benefit from adjuvant therapy. MATERIALS AND METHODS: All breast cancer pathology reports from our institution containing the word "sentinel" between July 1998 and December 2001 were reviewed. We obtained follow-up information on patients meeting Z11 eligibility criteria who did not undergo ALND. We also compared pathological characteristics between patients with 1 to 2 +SLNs and +LNs on ALND to those with no further +LNs. RESULTS: Of the 432 pathology reports reviewed, 38 were from patients meeting Z11 criteria who did not undergo ALND. At a median follow-up of 11.9 years, these patients had 5-year overall survival (OS) of 93.3% and 10-year OS of 79.3%. No patient had recurrent disease in the axilla. Of the 80 patients with 1 to 2 +SLNs who underwent ALND, tumors with +LNs on ALND were generally larger, nonductal histology, more likely to be estrogen receptor positive (ER(+)) and progesterone receptor positive (PR(+)), and less likely to be HER2(+). CONCLUSION: Our institution's 5-year OS (93.3%) for Z11-eligible patients closely resembled those from the Z11 trial (92.5%) and our 10-year data provide evidence of what to expect for Z11-enrolled patients with continued follow-up. Larger tumor, nonductal, ER(+), PR(+), and HER2- were predictive for further +LNs on ALND, which might reflect surgical bias. Published by Elsevier Inc.
Authors: Gary H Lyman; Armando E Giuliano; Mark R Somerfield; Al B Benson; Diane C Bodurka; Harold J Burstein; Alistair J Cochran; Hiram S Cody; Stephen B Edge; Sharon Galper; James A Hayman; Theodore Y Kim; Cheryl L Perkins; Donald A Podoloff; Visa Haran Sivasubramaniam; Roderick R Turner; Richard Wahl; Donald L Weaver; Antonio C Wolff; Eric P Winer Journal: J Clin Oncol Date: 2005-09-12 Impact factor: 44.544
Authors: Reshma Jagsi; Manjeet Chadha; Janaki Moni; Karla Ballman; Fran Laurie; Thomas A Buchholz; Armando Giuliano; Bruce G Haffty Journal: J Clin Oncol Date: 2014-08-18 Impact factor: 44.544
Authors: Armando E Giuliano; Kelly K Hunt; Karla V Ballman; Peter D Beitsch; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Linda M McCall; Monica Morrow Journal: JAMA Date: 2011-02-09 Impact factor: 56.272
Authors: Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi Journal: Lancet Oncol Date: 2013-03-11 Impact factor: 41.316
Authors: Anthony Lucci; Linda Mackie McCall; Peter D Beitsch; Patrick W Whitworth; Douglas S Reintgen; Peter W Blumencranz; A Marilyn Leitch; Sukumal Saha; Kelly K Hunt; Armando E Giuliano Journal: J Clin Oncol Date: 2007-05-07 Impact factor: 44.544